These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

500 related articles for article (PubMed ID: 33012578)

  • 21. Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
    Matsubara N; de Bono J; Olmos D; Procopio G; Kawakami S; Ürün Y; van Alphen R; Flechon A; Carducci MA; Choi YD; Hotte SJ; Korbenfeld E; Kramer G; Agarwal N; Chi KN; Dearden S; Gresty C; Kang J; Poehlein C; Harrington EA; Hussain M
    Clin Cancer Res; 2023 Jan; 29(1):92-99. PubMed ID: 36318705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 23. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.
    Smith MR; Scher HI; Sandhu S; Efstathiou E; Lara PN; Yu EY; George DJ; Chi KN; Saad F; Ståhl O; Olmos D; Danila DC; Mason GE; Espina BM; Zhao X; Urtishak KA; Francis P; Lopez-Gitlitz A; Fizazi K;
    Lancet Oncol; 2022 Mar; 23(3):362-373. PubMed ID: 35131040
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PARP inhibitors in castration-resistant prostate cancer.
    Tripathi A; Balakrishna P; Agarwal N
    Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olaparib Targets Some Advanced Prostate Cancers.
    Cancer Discov; 2016 Jan; 6(1):OF1. PubMed ID: 26658963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stratifying prostate patients for olaparib.
    Cancer Discov; 2015 Jun; 5(6):568-9. PubMed ID: 25904654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective.
    Matsumoto T; Shiota M; Blas L; Eto M
    Cancer Manag Res; 2022; 14():2389-2397. PubMed ID: 35967752
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
    VanderWeele DJ; Hussain M
    Clin Adv Hematol Oncol; 2020 Dec; 18(12):808-815. PubMed ID: 33406057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.
    Zhu J; Tucker M; Wang E; Grossman JS; Armstrong AJ; George DJ; Zhang T
    Clin Genitourin Cancer; 2017 Dec; 15(6):e1137-e1141. PubMed ID: 28780018
    [No Abstract]   [Full Text] [Related]  

  • 30. First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors.
    Takagi M; Ogawa C; Iehara T; Aoki-Nogami Y; Ishibashi E; Imai M; Kimura T; Nagata M; Yasuhara M; Masutani M; Yoshimura K; Tomizawa D; Ogawa A; Yonemori K; Morishita A; Miyamoto S; Takita J; Kihara T; Nobori K; Hasebe K; Miya F; Ikeda S; Shioda Y; Matsumoto K; Fujimura J; Mizutani S; Morio T; Hosoi H; Koike R
    Cancer; 2022 Aug; 128(15):2949-2957. PubMed ID: 35593736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
    Li L; Karanika S; Yang G; Wang J; Park S; Broom BM; Manyam GC; Wu W; Luo Y; Basourakos S; Song JH; Gallick GE; Karantanos T; Korentzelos D; Azad AK; Kim J; Corn PG; Aparicio AM; Logothetis CJ; Troncoso P; Heffernan T; Toniatti C; Lee HS; Lee JS; Zuo X; Chang W; Yin J; Thompson TC
    Sci Signal; 2017 May; 10(480):. PubMed ID: 28536297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
    Kim JW; McKay RR; Radke MR; Zhao S; Taplin ME; Davis NB; Monk P; Appleman LJ; Lara PN; Vaishampayan UN; Zhang J; Paul AK; Bubley G; Van Allen EM; Unlu S; Huang Y; Loda M; Shapiro GI; Glazer PM; LoRusso PM; Ivy SP; Shyr Y; Swisher EM; Petrylak DP
    J Clin Oncol; 2023 Feb; 41(4):871-880. PubMed ID: 36256912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
    Dhawan M; Ryan CJ; Ashworth A
    Oncologist; 2016 Aug; 21(8):940-5. PubMed ID: 27317574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The emerging role of PARP inhibitors in prostate cancer.
    Stellato M; Guadalupi V; Sepe P; Mennitto A; Claps M; Zattarin E; Verzoni E; Valdagni R; De Braud FG; Santini D; Tonini G; Procopio G
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):715-726. PubMed ID: 32758032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Lu E; Thomas GV; Chen Y; Wyatt AW; Lloyd P; Youngren J; Quigley D; Bergan R; Bailey S; Beer TM; Feng FY; Small EJ; Alumkal JJ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):933-937. PubMed ID: 30099369
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
    Li J; Wang R; Kong Y; Broman MM; Carlock C; Chen L; Li Z; Farah E; Ratliff TL; Liu X
    Mol Cancer Ther; 2017 Mar; 16(3):469-479. PubMed ID: 28069876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploiting defects in homologous recombination repair for metastatic, castration-resistant prostate cancer.
    Chau V; Madan RA; Figg WD
    Cancer Biol Ther; 2020 Oct; 21(10):884-887. PubMed ID: 32844710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
    Hammel P; Kindler HL; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Joo S; Yoo HK; Patel N; Golan T;
    Ann Oncol; 2019 Dec; 30(12):1959-1968. PubMed ID: 31562758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
    Leichman L; Groshen S; O'Neil BH; Messersmith W; Berlin J; Chan E; Leichman CG; Cohen SJ; Cohen D; Lenz HJ; Gold P; Boman B; Fielding A; Locker G; Cason RC; Hamilton SR; Hochster HS
    Oncologist; 2016 Feb; 21(2):172-7. PubMed ID: 26786262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.